EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Chemotherapy type and survival in young BRCA1/2 carriers with HER2-negative early breast cancer

Rinat Bernstein-Molho, Tal Sella, Virginia Delucchi, Florence Coussy, Hee Jeong Kim, Sabine Linn, Antonio Di Meglio, Katarzyna Pogoda, Ava Kwong, Elisa Agostinetto, Jyoti Bajpai, Yannick Van Herck und 35 weitere

European Journal of Cancer · 2026

DOI: 10.1016/j.ejca.2026.116937 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Rinat Bernstein-Molho und 46 weiteren Autor:innen. Beteiligte Einrichtung: Susanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, affiliated to Gray Faculty…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, BRCA1 Protein, Breast Neoplasms, BRCA2 Protein. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AIRC Italian Association for Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Evidence to guide (neo)adjuvant chemotherapy choices in carriers of germline BRCA1/BRCA2 pathogenic variants (BRCA carriers) with early breast cancer (BC) is limited. We evaluated the association of different chemotherapy regimens with survival outcomes in this population. METHODS: The BRCA BCY Collaboration (NCT03673306) is an international, multicenter, retrospective cohort study of BRCA carriers diagnosed with stage I-III BC at age ≤ 40 years, between 2000 and 2020. Disease-free survival (DFS) and overall survival (OS) were assessed among patients with HER2-negative disease treated with anthracycline-taxane, anthracycline-no-taxane, or non-anthracycline (neo)adjuvant chemotherapy. The association of platinum use with outcomes was evaluated in triple-negative breast cancer (TNBC). RESULTS: Among 4200 young BRCA carriers from 109 centres who received (neo)adjuvant chemotherapy for HER2-negative BC, 58.7% had TNBC. Median follow-up was 8.1 years (IQR, 4.7-12.6 years). Anthracycline-taxane, anthracycline-no-taxane, and non-anthracycline regimens were used in 74.4%, 19.3%, and 6.3% of patients, respectively. Platinum agents were administered in 19.8% of TNBC cases. After multivariable adjustment, no significant differences in DFS or OS were observed between anthracycline-no-taxane and anthracycline-taxane regimens (DFS adjusted hazard ratio [aHR] 0.88, 95% CI 0.73-1.05; OS aHR 1.20, 95% CI 0.87-1.67) or non-anthracycline regimens (DFS aHR 1.07, 95% CI 0.82-1.38; OS aHR 1.16, 95% CI 0.68-2.0). In TNBC, platinum use was not associated with improved outcomes. CONCLUSIONS: In young BRCA carriers with HER2-negative early BC, no statistically significant differences in survival outcomes were detected across different chemotherapy regimens. Our findings may inform future prospective studies evaluating chemotherapy de-escalation strategies in this genetically defined population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBRCA1 ProteinBreast NeoplasmsBRCA2 ProteinTriple Negative Breast NeoplasmsHumansFemaleAdultErb-b2 Receptor Tyrosine KinasesRetrospective StudiesAnthracyclinesHeterozygoteChemotherapy, AdjuvantNeoadjuvant TherapyDisease-Free SurvivalTaxoidsGerm-Line Mutation

Stichwörter der Autor:innen

BRCAChemotherapyEarly breast cancerSurvival outcomes

Substanzen

Erb-b2 Receptor Tyrosine KinasesBRCA1 ProteinERBB2 protein, humanBRCA1 protein, humanBRCA2 ProteinAnthracyclinesBRCA2 protein, humanTaxoids

Autor:innen und Institutionen

  • Susanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, affiliated to Gray Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israe…
  • Institute of Oncology, Sheba Medical Center, Tel Hashomer, Israel.
  • AOM - IRCCS Ospedale Policlinico San Martino, U.O. Epidemiologia Clinica - Clinical Trial Unit, Genova, Italy.
  • Department of Medical Oncology, Institut Curie - Institut of Women's Cancers, Paris, France.
  • Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Departments of Molecular Pathology and Medical Oncology, Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands.

Förderung

  • AIRC Italian Association for Cancer Research

Zitieren

APA

Bernstein-Molho, R., Sella, T., Delucchi, V., Coussy, F., Kim, H. J., Linn, S., Di Meglio, A., Pogoda, K., Kwong, A., Agostinetto, E., Bajpai, J., Van Herck, Y., Ferrari, A., Balmana, J., Moore, H. C. F., Peccatori, F. A., Partridge, A. H., Winocur, M., Renaud, T., …, & Lambertini, M. (2026). Chemotherapy type and survival in young BRCA1/2 carriers with HER2-negative early breast cancer. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.116937

Vancouver

Bernstein-Molho R, Sella T, Delucchi V, Coussy F, Kim HJ, Linn S, et al. Chemotherapy type and survival in young BRCA1/2 carriers with HER2-negative early breast cancer. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.116937

BibTeX
@article{BernsteinMolho2026,
  author = {Bernstein-Molho, Rinat and Sella, Tal and Delucchi, Virginia and Coussy, Florence and Kim, Hee Jeong and Linn, Sabine and Di Meglio, Antonio and Pogoda, Katarzyna and Kwong, Ava and Agostinetto, Elisa and Bajpai, Jyoti and Van Herck, Yannick and Ferrari, Alberta and Balmana, Judith and Moore, Halle C F and Peccatori, Fedro A and Partridge, Ann H and Winocur, Melina and Renaud, Tiphaine and Rousset-Jablonski, Christine and Lee, Jeong Eon and Toss, Angela and Paluch-Shimon, Shani and Wong, Stephanie M and Matikas, Alexios and Villarreal-Garza, Cynthia and Vernieri, Claudio and Lee, Minna and Guven, Deniz Can and Cui, Wanda and Ruddy, Kathryn J and Dieci, Maria Vittoria and Fruscio, Robert and De Marchis, Laura and Kemp, Zoe and Meireles, Pedro A and Razeti, Maria Grazia and Diz, Maria Del Pilar and Hwang, Shelley E and Puglisi, Fabio and Clatot, Florian and Yerushalmi, Rinat and Cichowska-Cwalinska, Natalia and Chirco, Alessandra and De Angelis, Carmine and Blondeaux, Eva and Lambertini, Matteo},
  title = {Chemotherapy type and survival in young BRCA1/2 carriers with HER2-negative early breast cancer},
  journal = {European Journal of Cancer},
  year = {2026},
  doi = {10.1016/j.ejca.2026.116937}
}
Kostenlos starten →